当前位置: 首页 >> 检索结果
1. Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study.
作者: Fiyyaz Ahmed-Jushuf.;Michael J Foley.;Shayna Chotai.;Christopher A Rajkumar.;Danqi Wang.;Florentina A Simader.;Krzysztof Macierzanka.;Kayla Chiew.;Sannidhya Misra.;Rupert Williams.;Klio Konstantinou.;Jehangir N Din.;Shah R Mohdnazri.;Peter D O'Kane.;Peter Haworth.;Sukhjinder S Nijjer.;Henry Seligman.;Thomas R Keeble.;John R Davies.;Gerald Clesham.;Jonathan Hinton.;James C Spratt.;Jason N Dungu.;Daniel Knight.;Tushar Kotecha.;Frank E Harrell.;James P Howard.;Darrel P Francis.;Matthew J Shun-Shin.;Rasha K Al-Lamee.
来源: Circulation. 2026年153卷23期1795-1812页
In stable coronary artery disease, the primary goal of percutaneous coronary intervention (PCI) is symptom relief. Fractional flow reserve (FFR) and nonhyperemic pressure ratios such as resting full-cycle ratio (RFR) are used to guide revascularization. Although these indices correlate with myocardial ischemia, they have never been validated against the onset of angina. The physiological thresholds for angina, FFRangina and RFRangina, angina (FFRangina at rest and during exercise remain undefined.
2. Optimal Ablation Strategies for Persistent Atrial Fibrillation With Heart Failure: Three-Year Follow-Up of a Prospective Multicenter Randomized Trial.
作者: Kaige Li.;Xinhua Wang.;Mu Qin.;Ping Ye.;Bing Han.;Weifeng Jiang.;Yu Zhang.;Qidong Zheng.;Anjing Ji.;Menghe Zhang.;Yanzhe Wang.;Shaohui Wu.;Kai Xu.;Changhao Xu.;Xu Liu.;Xumin Hou.
来源: Circ Arrhythm Electrophysiol. 2026年19卷4期e014394页
Catheter ablation has been shown to improve prognosis in patients with heart failure (HF) and atrial fibrillation (AF); however, the optimal ablation strategy remains undefined.
3. Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.
作者: Nicholas A Marston.;Brian A Bergmark.;Thomas A Prohaska.;Filipe A Moura.;André Zimerman.;Veronica J Alexander.;Yu Mi Kang.;Julia Weinland.;Xinhui Ran.;Sabina A Murphy.;Shuanglu Zhang.;Dan Li.;Maciej Banach.;Erik S G Stroes.;Robert Kiss.;Daniel Gaudet.;Michal Vrablik.;Assen Goudev.;Jeroen J Bax.;Matthew J Budoff.;Borek Foldyna.;Michael T Lu.;Sotirios Tsimikas.;Robert P Giugliano.;Marc S Sabatine.
来源: Circulation. 2026年153卷20期1539-1548页
Whether lowering triglyceride-rich lipoproteins and remnant cholesterol favorably modifies coronary atherosclerosis is unclear. Olezarsen, an antisense oligonucleotide that targets apolipoprotein C-III, reduces triglycerides by ~60% and remnant cholesterol by ~70%, has a neutral effect on LDL (low-density lipoprotein) cholesterol (LDL-C), and reduces apoB (apolipoprotein B) by ~15% in moderate hypertriglyceridemia. We investigated the effect of olezarsen on coronary plaque in adults with largely moderate hypertriglyceridemia.
4. Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN-STEMI Randomized Controlled Trial.
作者: Misa Fister.;Marko Noc.;Peter Radsel.;Matjaz Bunc.;Danilo Franco.;Tomaz Goslar.; .
来源: Circulation. 2026年153卷20期1526-1534页
Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for patients with ST-segment-elevation myocardial infarction (STEMI). We investigated the benefits and safety of pretreatment with unfractionated heparin (UFH) in patients with STEMI referred to primary PCI.
5. Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Noninferiority Randomized Trial.
作者: Mauro Biffi.;Giovanni Rovaris.;Ennio Carmine Luigi Pisanò.;Valeria Calvi.;Antonio Rapacciuolo.;Matteo Santamaria.;Giampiero Maglia.;Gabriele Zanotto.;Emanuele Bertaglia.;Gerardo Nigro.;Andrea Giomi.;Francesca Notarangelo.;Patrizia Pepi.;Giuliano D'Alterio.;Davide Castagno.;Antonio Dello Russo.;Antonino Nicosia.;Massimo Zecchin.;Matteo Bertini.;Antonio Duca.;Daniele Giacopelli.;Alessio Gargaro.;Giovanni Luca Botto.; .
来源: Circulation. 2026年153卷22期1707-1718页
The role of atrial pacing support is unclear in patients receiving cardiac resynchronization therapy-defibrillator (CRT-D) without sinus node dysfunction.
6. Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated With Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study.
作者: Mardi Gomberg-Maitland.;Ryan J Tedford.;David Langleben.;Stephan Rosenkranz.;Barry Miller.;Aaron D Jones.;Alessia Urbinati.;Ciaran J McMullan.;Alexandra G Cornell.;Jean-Luc Vachiery.
来源: Circulation. 2026年153卷19期1446-1459页
Combined post- and precapillary pulmonary hypertension in heart failure with preserved ejection fraction involves remodeling in both the heart and pulmonary vasculature. Despite significant mortality, there are no proven therapies.
7. Combined Anatomic and Functional Testing Identifies Patients With Obstructive Coronary Artery Disease Who Benefit From Revascularization.
作者: Oliver Buchhave Pedersen.;Laust Dupont Rasmussen.;Jacob Hartmann Søby.;Lars C Gormsen.;Evald Høj Christiansen.;Juhani Knuuti.;Morten Bøttcher.;Leslee Shaw.;Simon Winther.
来源: Circ Cardiovasc Imaging. 2026年19卷4期e019267页
In patients with obstructive coronary artery disease, early revascularization does not improve outcomes but may reduce angina symptoms. The objective of this study was to examine whether changes in health status outcomes following revascularization are explained by the extent of myocardial perfusion defects and improvement in myocardial perfusion.
8. Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial.
作者: Yunli Shen.;Chunyu Zeng.;Yingxian Sun.;Jian'an Wang.;Bo Yu.;Xiang Cheng.;Xiaogang Guo.;Dao Wen Wang.;Yue Li.;Wei Han.;Bingqing Zhou.;Hongzhuan Sheng.;Zhaoqi Huang.;Yigang Li.;Guosheng Fu.;Jidong Zhang.;Duanyang Xie.;Dandan Liang.;Yi Liu.;Bing Yang.;Qi Zhang.;Ran Duan.;Hongxiao Li.;Baowei Zhang.;Yizhang Wu.;Liang Zheng.;Jia He.;Shenglin Liu.;Dechun Yin.;Guozhe Sun.;Shu Zhang.;Xiaofan Guo.;Min Zhang.;Yiyi Wang.;Xiajun Hu.;Jing Zeng.;Xiaoli Yang.;Shufeng Li.;Ning Li.;Feng Hu.;Haifeng Wang.;Xinyang Hu.;Yaping Wang.;Cong Zeng.;Kai Wang.;Jian Yang.;Yan Wang.;Jinsheng Lai.;Luyun Wang.;Ke Xiong.;Guanghua Wang.;Qicheng Zou.;Beihua Shao.;Zhiwen Chen.;Yahan Wu.;Junwei Leng.;Jun Pu.;Changsheng Ma.;Yi-Han Chen.
来源: Circulation. 2026年153卷16期1196-1209页
Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression. Experimental studies have identified a functional cardiac glutamatergic system in which N-methyl-D-aspartate receptors regulate atrial electrophysiology. Preclinical studies show that pharmacological antagonism of N-methyl-D-aspartate receptors with memantine suppresses atrial arrhythmias.
9. MUTTON-HF: Rationale and Design of a Study of an Indigenous Food is Medicine Intervention.
作者: Lauren A Eberly.;Carmen George.;Sharon Sandman.;Denee Bex.;Karianne Jones.;Asia Yazzie.;Leah Gray.;Larissa Morgan.;Ada Tennison.;Conor Williams.;Matt Chandra.;Rebecca Wickre.;Bennett Wickre.;Mackenzie Bolas.;Remi Welbel.;Delaney Ignace.;Benjamin Feliciano.;DezBaa Damon-Mallette.;Erica Lindsey.;Paula Mora.;Maricruz Merino.;Enrique F Schisterman.;Sonya S Shin.
来源: Circ Heart Fail. 2026年19卷4期e014013页
Nutrition insecurity is a major driver of poor cardiovascular health in Indigenous communities. Medically tailored meals may improve heart failure outcomes and quality of life. There is growing momentum among Indigenous communities to reclaim traditional precontact foods to improve cardiovascular health. In this context, utilizing community-based-participatory methods, we designed MUTTON-HF (Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure)-an Indigenous culturally and medically tailored meals program that locally sources Native produce and meat and incorporates traditional Diné (Navajo) foods and recipes.
10. Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial.
作者: Mario Enrico Canonico.;Jessica Parr.;E Sebastian Debus.;Mark R Nehler.;Manesh R Patel.;Sonia S Anand.;Mark Svet.;Connie N Hess.;Warren H Capell.;Joseph Ycas.;Julian Chen.;Michael Szarek.;Eva Muehlhofer.;Lloyd P Haskell.;Scott D Berkowitz.;Rupert M Bauersachs.;Marc P Bonaca.
来源: Circ Cardiovasc Interv. 2026年19卷5期e015229页
Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) are at high risk of major adverse limb events (MALE) and major adverse cardiovascular events. The VOYAGER-PAD trial (Vascular Outcomes Study of Acetylsalicylic Acid Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) demonstrated that rivaroxaban 2.5 mg twice daily on top of antiplatelet therapy significantly reduced this risk. Whether the risk of major adverse cardiovascular events and MALE and the effect of rivaroxaban are consistent in patients with a history of prior LER versus those without has not been described.
11. NURSE-Led Care in Patients Undergoing Catheter Ablation for Atrial Fibrillation: The NURSECAT-AF Randomized Trial.
作者: Alba Cano-Valls.;Maria Antonia Martinez Monblan.;Esther Carro-Fernández.;Mireia Niebla.;Rebeca Domingo.;Sara Hevia-Puyo.;Montserrat Venturas-Nieto.;Roger Borras.;José María Tolosana.;Andreu Porta-Sánchez.;Jean-Baptiste Guichard.;Till F Althoff.;Ivo Roca-Luque.;Lluis Mont.;Eduard Guasch.
来源: Circ Arrhythm Electrophysiol. 2026年19卷3期e014149页
Atrial fibrillation (AF) is associated with reduced quality of life and frequent hospitalizations. Integrated nurse-led care (NLC) has proven beneficial in unselected AF patients, but evidence specific to patients undergoing catheter ablation is limited. We aimed to assess the impact of a structured nurse-led intervention in patients undergoing first-time AF ablation.
12. Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.
作者: Mahesh V Madhavan.;John Gregson.;Bjorn Redfors.;Shmuel Chen.;Joseph F Sabik.;Akiko Fujino.;Lak N Kotinkaduwa.;Dimitri Karmpaliotis.;Jeffrey W Moses.;Ori Ben-Yehuda.;Patrick W Serruys.;Stuart Pocock.;A Pieter Kappetein.;Akiko Maehara.;Gregg W Stone.
来源: Circulation. 2026年153卷12期890-901页
Limited data are available regarding the relative rates, etiology, and long-term prognostic implications of spontaneous myocardial infarction (MI) after percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery for left main coronary artery disease (LMCAD).
13. Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins.
作者: Lukas E Schmidt.;Sean A Burnap.;Bhawana Singh.;Kaloyan Takov.;Sylvain Losdat.;Lore Schrutka.;Lukas Galli.;Konstantinos Theofilatos.;Georg W Otto.;Christian Hengstenberg.;Ioanna Tzoulaki.;Irene M Lang.;Konstantinos C Koskinas.;Walter S Speidl.;Lorenz Räber.;Manuel Mayr.
来源: Circ Genom Precis Med. 2026年19卷2期e005345页
PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition is a potent cholesterol-lowering strategy. This study examined the effects of PCSK9 monoclonal antibodies (mAbs) and high-intensity statins beyond low-density lipoprotein cholesterol reduction, which are not fully defined, particularly in patients with acute myocardial infarction (MI).
14. Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.
作者: Julian S Haimovich.;Shinwan Kany.;Yuchiao Chang.;Leila H Borowsky.;David D McManus.;Steven J Atlas.;Daniel E Singer.;Steven A Lubitz.;Patrick T Ellinor.;Shaan Khurshid.
来源: Circulation. 2026年153卷6期367-378页
Stressor-associated atrial fibrillation (AF), defined as newly diagnosed AF in the setting of a reversible physiological stressor, is common. However, risk factors, outcomes, and current management practices remain poorly understood.
15. Balloon- Versus Self-Expanding Transcatheter Valves for Failed Small Surgical Aortic Bioprostheses: 3-Year Results of the LYTEN Trial.
作者: Pedro Cepas-Guillén.;Amr E Abbas.;Vicenç Serra.;Victoria Vilalta.;Luis Nombela-Franco.;Ander Regueiro.;Karim M Al-Azizi.;Ayman Iskander.;Lenard Conradi.;Jessica Forcillo.;Scott Lilly.;Álvaro Calabuig.;Eduard Fernandez-Nofrerias.;Siamak Mohammadi.;Carlos Giuliani.;Emilie Pelletier-Beaumont.;Philippe Pibarot.;Josep Rodés-Cabau.
来源: Circ Cardiovasc Interv. 2026年19卷3期e016255页
Data comparing valve systems in the valve-in-valve transcatheter aortic valve replacement (TAVR) field have been obtained from retrospective studies. This prespecified secondary analysis of the LYTEN randomized trial (Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprostheses) aims to compare the 3-year hemodynamic performance and clinical outcomes between balloon-expandable valves (BEV) SAPIEN 3/ULTRA (Edwards Lifesciences) and self-expanding valves (SEV) Evolut R/PRO/PRO+ (Medtronic) in valve-in-valve TAVR.
16. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF.
作者: Jawad H Butt.;Alasdair D Henderson.;Pardeep S Jhund.;Brian L Claggett.;Akshay S Desai.;Maria Borentain.;Katja Rohwedder.;Rania Dayoub.;Yoriko De Sanctis.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Adriaan A Voors.;Johann Bauersachs.;Cândida Fonseca.;Gerard C M Linssen.;Mark C Petrie.;Morten Schou.;Subodh Verma.;Faiez Zannad.;Bertram Pitt.;Muthiah Vaduganathan.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2026年19卷2期e013201页
The prevalence and prognostic significance of liver biomarkers in heart failure (HF) with mildly reduced or preserved ejection fraction are uncertain, with both potential hemodynamic and metabolic contributions to liver dysfunction in these patients. We evaluated the prevalence and prognostic value of liver biomarkers and assessed the effects of the nonsteroidal mineralocorticoid receptor antagonist finerenone on these biomarkers and clinical outcomes in FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure).
17. Dynamic Change of Coronary Artery Geometry After Bioadaptor Implantation: A Single-blind Randomized Controlled Trial.
作者: Cheng-Hsuan Tsai.;Han-Hsuan Chu.;Ching-Chang Huang.;Chih-Fan Yeh.;Ying-Hsien Chen.;Mao-Shin Lin.;Tsung-Yu Ko.;Chun-Kai Chen.;Yu-Cheng Huang.;Pin-Yi Chiang.;Wen-Jeng Lee.;Hsien-Li Kao.
来源: Circ Cardiovasc Interv. 2026年19卷2期e016191页
The DynamX bioadaptor, a novel coronary implant, is designed to restore vessel function when the thin polymer coating covering the helical strands resorbs 6 months post-percutaneous coronary intervention. We aimed to evaluate vessel conformability 1 year after percutaneous coronary intervention with the bioadaptor, compared with conventional drug-eluting stents (DESs).
18. Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial.
作者: Ayodele Odutayo.;Deepak L Bhatt.;Vikas S Sridhar.;Michael Szarek.;Christopher P Cannon.;Lawrence A Leiter.;Darren K McGuire.;Julia B Lewis.;Renato D Lopes.;Benjamin M Scirica.;Kausik K Ray.;Michael J Davies.;Phillip Banks.;Manon Girard.;Subodh Verma.;Jacob A Udell.;Bertram Pitt.;Ph Gabriel Steg.;David Z I Cherney.
来源: Circ Heart Fail. 2026年19卷3期e013054页
The 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America heart failure (HF) classification incorporates cardiac biomarkers to identify early risk of HF. The HF stages may also guide the prognosis and management of cardiovascular and kidney-related events.
19. Delay From First Symptoms in Patients Presenting With STEMI and Cardiogenic Shock: Insights From the DanGer Shock Trial.
作者: Lisette Okkels Jensen.;Rasmus Paulin Beske.;Hans Eiskjær.;Norman Mangner.;Amin Polzin.;P Christian Schulze.;Carsten Skurk.;Peter Nordbeck.;Peter Clemmensen.;Vasileios Panoulas.;Sebastian Zimmer.;Andreas Schäfer.;Nikos Werner.;Lene Holmvang.;Kristian Wachtell.;Thomas Engstøm.;Nanna Louise Junker Udesen.;Henrik Schmidt.;Anders Junker.;Christian Juhl Terkelsen.;Steffen Christensen.;Axel Linke.;Jacob Eifer Møller.;Christian Hassager.; .
来源: Circ Cardiovasc Interv. 2026年19卷3期e015718页
Microaxial flow pump (mAFP) use in selected patients with ST-segment-elevation myocardial infarction complicated by cardiogenic shock improves survival. The present study aimed to assess the influence of delay from first symptoms to randomization on the benefit of an mAFP in patients with ST-segment-elevation myocardial infarction complicated by cardiogenic shock.
20. Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.
作者: Sergio Leonardi.;Antonio Landi.;Andrea Zito.;Mattia Branca.;Enrico Frigoli.;Giuseppe Ando'.;Carlo Briguori.;Paolo Calabro.;Andrea Gagnor.;Roberto Garbo.;Dik Heg.;Ugo Limbruno.;Andrea Milzi.;Elmir Omerovic.;Filippo Russo.;Manel Sabaté.;Andrea Santarelli.;Gennaro Sardella.;Paolo Tosi.;Arnoud W J Van't Hof.;Pascal Vranckx.;Marco Valgimigli.
来源: Circulation. 2026年153卷4期230-242页
The universal definition of percutaneous coronary intervention (PCI)-related myocardial infarction (MI) has been substantially updated over the years, including an increase in the biomarker threshold (from 3 to 5 times the upper reference limit) and the introduction of ancillary criteria such as ischemic symptoms and electrocardiographic or angiographic complication. The impact of these changes in patients with acute coronary syndrome (ACS) remains incompletely understood. The objective of this study was to compare prognostic implications of evolving universal definitions of PCI-MI in a large cohort of patients with ACS from the MATRIX trial (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX).
|